Featured Research

from universities, journals, and other organizations

Cervical Cancer Vaccine Proves Effective: Test Results

Date:
October 12, 2005
Source:
University of Queensland
Summary:
Final-stage clinical trials of a cervical cancer vaccine developed by University of Queensland (UQ) scientists, have shown the drug to be 100 percent effective.

Pioneering research by Professor Ian Frazer from UQ's Centre for Immunology and Cancer Research led to the development of the vaccine.
Credit: Image courtesy of University of Queensland

Final-stage clinical trials of a cervical cancer vaccinedeveloped by University of Queensland (UQ) scientists, have shown thedrug to be 100 per cent effective.

The results of the Phase IIItrials were announced overnight in New York by internationalpharmaceutical company Merck & Co. who are developing the product.

Itwas the pioneering research work of Professor Ian Frazer from UQ'sCentre for Immunology and Cancer Research (CICR) that led to thedevelopment of the vaccine.

Professor Frazer said he was delighted by the news and pleased to have been involved in the vaccine's creation.

“Itis very rare, almost unheard of, to achieve a 100% efficacy rate in anytreatment, so these results are truly wonderful,” he said.

“It isthe first time in the world that a vaccine designed to prevent cancerhas been developed, and it has happened right here in Australia.

“Itis very encouraging to see such great results coming out of Australianresearch, and developed in conjunction with Australian company CSL, andinternational pharmaceutical company Merck & Co.

“It is sad that Dr Jian Zhou, who was my research partner, passed away before the work was publicly recognised.”

Thevaccine is called Gardasil™ and it is expected to be submitted forapproval by the United States Food and Drug Administration (FDA) withinthe next two months.

If the drug is approved by the FDA asanticipated by the international scientific community, the vaccineshould be commercially available in early 2006.

The trial is partof the ongoing phase III program for Gardasil™, which has involved morethan 25,000 people in 33 countries worldwide in total.

Women aged16 years to 26 years were chosen at random to receive a three-doseregimen of either Gardasil™ or placebo at Day 1, Month 2, and Month 6.

Gardasil™was successful in preventing 100 per cent of cases of high-gradepre-cancer and non-invasive cancer associated with human papillomavirus(HPV) strains Type 16 and 18, which cause cervical cancer.

These clinical trial results mirror the outcomes of earlier stage tests also carried out by Merck & Co.

Noneof the women involved in the trial were forced to pull out as a resultof adverse side-affects. The most serious adverse side-affect reportedwas local discomfort at the injection site.

Cervical cancer is one of the few human cancers that is known to be directly caused by a viral infection.

HPVstrain types 16 and 18 lead to the development of cervical cancer, adisease that is the second leading cause of cancer amongst women.

More than 500,000 cases are diagnosed annually and it kills an estimated 275,000 women around the world every year.

Othertypes of the HPV virus cause genital and skin warts. The HPV`s thatconvey a high risk of cervical cancer are contracted by up to anestimated 70 per cent of sexually active women.

Professor Frazersaid Gardasil™ would only protect women who were not infected with HPV,but he hoped to change this in the future.

“My major focus thesedays, as indeed it was right back in the beginning, is on developing avaccine to treat these existing infections,” he said.

“We have produced a second vaccine which we hope will do this, however clinical trials are still at a very early stage.

“A therapeutic vaccine to treat already infected individuals is much harder to develop than a vaccine to prevent infection.”

ProfessorFrazer hails from Scotland and trained as a renal physician andclinical immunologist in Edinburgh before immigrating to Australia in1980.

In addition to his responsibilities as Head of CICR, he isthe director of a biotechnology start up company, Coridon, which has aninterest in optimising and targeting polynucle vaccine proteinexpression.


Story Source:

The above story is based on materials provided by University of Queensland. Note: Materials may be edited for content and length.


Cite This Page:

University of Queensland. "Cervical Cancer Vaccine Proves Effective: Test Results." ScienceDaily. ScienceDaily, 12 October 2005. <www.sciencedaily.com/releases/2005/10/051011065519.htm>.
University of Queensland. (2005, October 12). Cervical Cancer Vaccine Proves Effective: Test Results. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/10/051011065519.htm
University of Queensland. "Cervical Cancer Vaccine Proves Effective: Test Results." ScienceDaily. www.sciencedaily.com/releases/2005/10/051011065519.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins